ACXP News and Press, Acurx Pharmaceuticals Inc. From 06/17/25

2025-06-17 07:37:10 ET DENVER, Colo., Jun 17, 2025 ( 247marketnews.com )- Acurx Pharmaceuticals (NASDAQ:ACXP) announced today the publication of positive Phase 2b clinical trial results for its lead candidate, ibezapolstat, in Lancet Microbe . The data highlight a 94% clinical c...

Acurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDI PR Newswire As previously reported, 15 out of 16 (94%) patients in Phase 2b in the Per Protocol Population experienced Clinical Cure (CC) and all 15 of 15 (100%) remained ...

Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Federation of American Societies for Experimental Biology Scientific Conference PR Newswire Results are from Acurx's ...

2025-05-21 16:37:21 ET More on Acurx Pharmaceuticals Acurx signals progress in Phase 3 ibezapolstat program with $12M credit line following regulatory alignment Acurx Pharmaceuticals announces resale of 8.4M shares Seeking Alpha’s Quant Rating on Acurx Pharmac...

2025-05-13 14:00:45 ET More on Acurx Pharmaceuticals Acurx Pharmaceuticals, Inc. (ACXP) Q1 2025 Earnings Call Transcript Acurx Pharmaceuticals, Inc. (ACXP) Q4 2024 Earnings Call Transcript Acurx Pharmaceuticals announces resale of 8.4M shares Acurx Pharmaceut...

2025-05-13 13:59:17 ET Acurx Pharmaceuticals, Inc. (ACXP) Q1 2025 Earnings Conference Call May 13, 2025 08:00 AM ET Company Participants Robert Shawah - Co-Founder and CFO David Luci - President and CEO Conference Call Participants Joanne Lee - Maxim Grou...

2025-05-13 08:07:38 ET More on Acurx Pharmaceuticals Acurx Pharmaceuticals, Inc. (ACXP) Q4 2024 Earnings Call Transcript Acurx Pharmaceuticals announces resale of 8.4M shares Acurx Pharmaceuticals stock sinks on $1.1M direct offering Seeking Alpha’s Qu...

Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update PR Newswire STATEN ISLAND, N.Y. , May 13, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical compan...

urban-gro Inc. (UGRO) is expected to report for quarter end 2025-03-31 Karman Holdings Inc. (KRMN) is expected to report $0.02 for Q1 2025 PyroGenesis Inc Com (PYRGF) is expected to report for quarter end 2025-03-31 GeoVax Labs Inc. (GOVX) is expected to report $-0.59 for Q1 2025 ...

Acurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business Update PR Newswire STATEN ISLAND, N.Y. , April 30, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Com...